Subscribe

Shitanshu Uppal

LEAP-001: Lenvatinib plus Pembrolizumab vs. Chemotherapy as First-Line Therapy for Advanced Endometrial Cancer

First-line lenvatinib plus pembrolizumab did not significantly improve PFS or OS compared to chemotherapy in mismatch repair-proficient (pMMR) advanced endometrial cancer. Toxicity was higher in the experimental arm but manageable. dMMR exploratory analysis shows promise in this subgroup.

Anticoagulation and Bleeding

Chemotherapy Infusion Emergencies

Publications Update # 82

Book recommendation - Get It Done by Ayelet Fishbach, MITO-18 trial summary and discussion points, NEJM paper - BALANCE trial, Trial flashback - road to carboplatin and taxol video (5 mins)

GYOEDU Resident: Non-Epithelial Tumors of the Ovary

Hi there, This video is a part of the GYOEDU

CHIPOR: Secondary Debulking and HIPEC in Platinum-Sensitive Recurrent Ovarian Cancer

HIPEC combined with cytoreductive surgery significantly improved overall survival and progression-free survival in recurrent ovarian cancer

Publications Update # 81

Video summary of CHIPOR trial, study summary of CHIPOR trial

Management of Febrile Neutropenia

GYOEDU Resident: Recurrent Ovarian Cancer

Management of STIC in Patients Undergoing RRSO